Learn, Analyse & Invest
only with
only with
+91
Download Orca
Eris Lifesciences Ltd.
Eris Lifesciences
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹184.01 Cr.
| EX-Date | Purpose |
|---|---|
| 13 05 2021 | Audited Results |
| 29 07 2021 | Quarterly Results & Interim Dividend |
| 29 10 2021 | Quarterly Results |
| 28 01 2022 | Quarterly Results |
| 03 05 2022 | Quarterly Results |
| 05 08 2022 | Quarterly Results & Interim Dividend |
| 20 10 2022 | Quarterly Results |
| 17 01 2023 | Quarterly Results |
| 17 05 2023 | Audited Results |
| 07 08 2023 | Quarterly Results |
| 08 11 2023 | Quarterly Results |
| 13 02 2024 | Quarterly Results |
| 25 10 2024 | Quarterly Results |
| 04 02 2025 | Quarterly Results |
| 07 02 2025 | Interim Dividend |
| 19 05 2025 | Audited Results |
| 05 08 2025 | Quarterly Results |
| 12 11 2025 | Quarterly Results |
| 24 11 2025 | Preferential Issue of shares Inter-alia, to consider the proposal of issuance ofequity shares of the Company by way of a preferential issue for consideration other than cash, in accordance with the provisions of the Companies Act, 2013, as amended, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable law, in connection with a potential acquisition of the remaining 30% (thirty percent) equity stake in Swiss Parenterals Limited by the Company, subject to approval of the members of the Company and other regulatory and/or statutory approvals, as applicable. The Board of Directors would also consider convening an extra-ordinary general meeting / postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of preferential issue, as required |
| 13 02 2026 | Quarterly Results |
News
